<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        20-5083-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CARELIO
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        METOPROLOL SUCCINATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        23.40
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ACINO PHARMA AG" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ACINO PHARMA AG
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ACINO PHARMA AG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C07AB02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance in Carelio is metoprolol. Metoprolol belongs to the group of medicines<br />called beta-blockers and is used for the treatment of high blood pressure (hypertension), the<br />long term treatment of angina pectoris (tightness in the chest), chronic heart failure (chronic<br />cardiac insufficiency), heart rhythm disorders and cardiovascular disorders with palpitations,<br />as well as for the prevention of migraine.<br />Due to its special formulation, which allows controlled release of the active substance, the<br />effect of Carelio prolonged-release tablets usually lasts 24 hours.<br />Carelio may be taken only when prescribed by a doctor and with ongoing medical monitoring.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>When must Carelio not be used?<br />Carelio must not be taken if you have a known hypersensitivity to the active substance<br />metoprolol, to any of the other ingredients or to any other medicines that belong to the group<br />called beta-blockers.<br />In addition, Carelio must not be taken:<br />‒ if you have problems with the passage of electrical impulses from the heart&rsquo;s upper<br />chambers (atria) to the lower chambers (ventricles) (2nd- and 3rd<br />‒ if you have an irregular heartbeat which is often very slow and sometimes very<br />fast (except if you have a permanent pacemaker),<br />-degree AV block),<br />Carelio PIL_en Pg. 1<br />‒ if you have problems with the passage of electrical impulses between the sinus<br />node and upper chamber of the heart (atrium),<br />‒ if you are suffering from shock,<br />‒ if you have a weak heart together with fluid accumulation in the lungs, poor blood<br />circulation or low blood pressure,<br />‒ if your resting pulse rate before treatment is less than 50 beats per minute,<br />‒ if you have abnormally low blood pressure,<br />‒ if the circulation in your arms or legs is severely reduced,<br />‒ if you are prone to bronchial asthma or bronchial spasms.<br />When caution is needed while taking Carelio?<br />This medicine may affect your reactions, your ability to use tools and machinery and your<br />ability to drive.<br />If you are taking other medicines for breathing disorders at the same time, the dosages of the<br />various medicines must be readjusted by a doctor.<br />Caution is advised in case of diabetes mellitus, certain heart conditions, heart conduction<br />disorders, circulatory disorders, impaired liver function as well as in patients with a hormoneproducing<br />tumour (phaeochromocytoma).<br />Before surgery the anaesthetist should be informed that you are taking Carelio .<br />Some medications (including nose and eye drops) as well as alcohol may interfere with the<br />action of Carelio if taken at the same time.<br />Tell your doctor or pharmacist if you suffer from other illnesses, have any allergies or are<br />taking any other medicines (including those purchased without a prescription).<br />May Carelio be taken during pregnancy or breast feeding?<br />If you are pregnant or intend to become pregnant, or if you are breast feeding, consult your<br />doctor before taking Carelio .<br />Carelio , a beta-blocker, may harm the foetus or induce premature labour.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Carelio prolonged-release tablets are taken once daily with a glass of water. They can be<br />taken with or without meals. The Carelio prolonged-release tablets have a score line and can<br />be easily divided. However, they must not be crushed or chewed.<br />The doctor will prescribe the right dose for you based on regular tests/examinations. In<br />general, the following dosage guidelines apply:<br />High blood pressure (hypertension)<br />In cases of mild to moderate high blood pressure, take 1 prolonged-release tablet of Carelio<br />50, once daily in the morning. The dosage may be increased by the doctor to 1 prolongedrelease<br />tablet of Carelio 100 or Carelio 200. If necessary, your doctor may prescribe an<br />additional blood-pressure lowering medicine for you.<br />Adults<br />For children from 6 years of age, the dosage depends on body weight. Your doctor will<br />determine the correct dosage for your child and monitor it regularly.<br />Children and adolescents (6 to 16 years of age)<br />The use of Carelio by children below 6 years of age is not recommended.</p><p>Angina pectoris (tightness in the chest)<br />In cases of angina pectoris, take 1 prolonged-release tablet of Carelio 100 or Carelio 200 once<br />daily. If necessary, your doctor may increase the dose.<br />Chronic heart failure (chronic cardiac insufficiency)<br />In cases of chronic heart failure, the initial dose is Carelio 25 mg once daily for 2 weeks.<br />In cases of severe heart failure, the doctor may prescribe you a lower initial dose of 12.5 mg<br />once daily (half a Carelio 25 mg prolonged-release tablet). The dose can then be doubled<br />every two weeks up to 200 mg Carelio once daily.<br />Heart rhythm disorders<br />In cases of heart rhythm disorders, take 1 prolonged-release tablet of Carelio 100 or Carelio<br />200 once daily. If necessary, your doctor may increase the dose.<br />Cardiovascular disorders with palpitations<br />In cases of cardiovascular disorders, take 1 prolonged-release tablet of Carelio 100 once daily.<br />If necessary, your doctor may increase the dose.<br />Prevention of migraine<br />For the prevention of migraine, take 1 prolonged-release tablet of Carelio 100 or Carelio 200<br />once daily.<br />You must not stop taking Carelio suddenly. The doctor will decide how to reduce the dose<br />gradually.<br />Do not change the prescribed dosage yourself. If you think that the effect of the medicine is<br />too weak or too strong, talk to your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The following side effects may occur when taking Carelio :<br />Very common: tiredness. Common: dizziness, headache, nausea, abdominal pain, shortness of<br />breath, abnormally slow pulse, cold hands and feet, diarrhoea and constipation.<br />Uncommon: exhaustion, vomiting, pain around the heart, oedema (water retention in the<br />tissues), muscle cramps, drowsiness, sleeplessness, nightmares, impaired concentration,<br />depression, increased sweating, rash, asthma attacks and weight gain. Rare: palpitations,<br />irregular heartbeat, heart failure, nervousness, anxiety, visual disturbances, dry and irritated<br />eyes, inflammation of the lining of the nose, muscle weakness, dry mouth, hair loss, libido<br />disorders and erectile dysfunction.<br />Very rare: mood swings, impaired memory, confusion, hallucinations, ringing in the ears,<br />taste disturbances, sensitivity of the skin to light, worsening of psoriasis and joint pain.<br />If you notice any side effects not described here, you should tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not store above 25&deg;C and keep out of the sight and reach of children.<br />This medicine may be used only up to the date marked with &ldquo;EXP&rdquo; on the pack. If you have<br />out-of-date medication, return it to the pharmacy for disposal.<br />Further information may be obtained from your doctor or pharmacist. These persons have the<br />detailed prescribing information at their disposal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1 prolonged-release tablet of Carelio 25, 50, 100 and 200 contains 23.75 mg, 47.5 mg, 95 mg<br />and 190 mg respectively of metoprolol succinate, equivalent to 25 mg, 50 mg, 100 mg and<br />200 mg respectively of metoprolol tartrate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Packs of 30, 50 and 100 prolonged-release tablets are available (Carelio 25, Carelio 50,
Carelio 100, Carelio 200).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Acino Pharma AG, Liesberg (Switzerland)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                March 2015
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>المادة الفع الة في كاريليو هي ميتوبرولول. ينتمي ميتوبرولول إلى مجموعة من الأدوية تسمى حاصرات بيتا وتستخدم لعلاج ارتفاع<br />ضغط الدمَّ، وعلاج الذبحة الصدرية طويل الأمد (ضيق في الصدر)، فشل القلب المزمن (قصور مزمن بوظائف القلب)،<br />اضطرابات النظم القلبي واضطرابات القلب والأوعية الدمَّوية المصحوب بخفقان، وكذلك لمنع الإصابة بالصداع النصفي.<br />نظرًا لتركيبته الخاصة، التي تسمح بالإفراز المُضبط للمادة الفعَّالة، يدوم تأثير كاريليو أقراصممتدة الإفراز عادة لمدة ۲٤ ساعة.<br />لا يمكن تناوُل كاريليو إلا عند وصفه من قبل الطبيب مع المراقبة الطبية المستمرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يجب عدم تناوُل كاريليو إذا كنت مصاباً بفرط الحساسية المعروف تجاه المادة الفعاّلة ميتوبرولول، أو تجاه أي من المكونات<br />الأخرى أو تجاه أية أدوية أخرى تنتمي إلى مجموعة الأدوية التي تسمى حاصرات بيتا.<br />بالإضافة إلى ذلك، يجب تجنُّب تناوُل كاريليو في الحالات التالية:<br />‒ إذا كان لديك مشاكل خاصة بمرور الإشارات الكهربائية من غرف القلب العليا (الأذينين) إلى الغرف السفلى (البطينين)<br />(الإحصار الأذيني البطيني من الدرجة الثانية والثالثة).<br />‒ إذا كنت تعاني من عدم انتظام ضربات القلب والذي غالبًا ما يكون بطيء جدًا وأحيانًا سريع جدًا (باستثناء في حالة إذا<br />كان لديك منظم دائم لضربات القلب).<br />‒ إذا كان لديك مشاكل خاصة بمرور الإشارات الكهربائية بين العقُد الجيبية والغرفة العليا للقلب (الأذينين).<br />‒ إذا كنت تعُاني من صدمة.<br />‒ إذا كنت مصابًا بضعف القلب مصحوب بتراكُم السائل في الرئتين، أو ضعف الدورة الدموية أو انخفاض ضغط الدم.<br />‒ إذا كان معدل النبض لديك أثناء الراحة قبل العلاج أقل من ٥۰ ضربة في الدقيقة.<br />‒ إذا كان لديك انخفاض غير طبيعي في ضغط الدَّم.<br />‒ إذا كنت مصاباً بقصور الدورة الدموية في ذراعيك أو ساقيك بشدة.<br />‒ إذا كنت معرضًا للإصابة بمرض الربو الشُّعبَي أو تقلصات الشعب الهوائية.<br />متى يلزم توخي الحذر أثناء تناوُل كاريليو؟<br />قد يؤثر هذا الدواء على ردود أفعالك وفي قدرتك على استخدام الأدوات أو الآلات وقدرتك على القيادة.<br />إذا كنت تتناول أدوية أخرى لعلاج اضطرابات التنفس في نفس الوقت، فيجب تعديل جرعة الأدوية المختلفة من قبل الطبيب.<br />ينُصح بتوخي الحذر في حالة الإصابة بمرض السُّكَّرِيّ وبعض حالات القلب، واضطرابات التوصيل بالقلب، واضطرابات الدورة<br />الدموية، وقصور وظائف الكبد وكذلك في المرضى الذين يعانون من ورم مفرز للهرمونات (ورم القواتم).<br />قبل الخضوع للجراحة يجب إخبار طبيب التخدير بأنك تتناول كاريليو.<br />قد تتداخل بعض الأدوية (بما في ذلك قطرات الأنف والعين) وكذلك الكحوليات مع عمل كاريليو إذا تم تناوُلها في الوقت نفسه.<br />يرُجى إبلاغ طبيبك أو الصيدلي الخاص بك إذا كنت تعاني من أي أمراض أخرى أو أي حساسية، أو إذا كنت تتناول أية أدوية<br />أخرى (بما في ذلك الأدوية التي يتم شراؤها بدون وصفة طبية).<br />هل يجوز تناوُل كاريليو خلال فترة الحمل أو الرضاعة الطبيعية؟<br />استشيري طبيبك قبل تناوُل كاريليو إذا كنتِ حاملا أو تنوين الحمل، أو كنتِ مرضعاً.<br />قد يضر كاريليو، وهو أحد حاصرات بيتا، بالجنين أو قد يحفز المخاض المبكر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يتم تناوُل كاريليو أقراص ممتدة الإفراز مرة واحدة يومياً مع كوب من الماء. يمكن تناوُل الأقراص مع الوجبات أو بدونها. تكون<br />أقراص كاريليو ممتدة الإفراز بها خط تقسيم ومن الممكن تقسيمها بسهولة. مع ذلك، يجب عدم طحن الأقراص أو مضغها.<br />سيصف لك الطبيب الجرعة الصحيحة لك اعتماداً على الاختبارات/ الفحوصات المنتظمة. بصفة عامة، يتم تطبيق إرشادات<br />الجرعة التالية:<br />ارتفاع ضغط الدم<br />البالغون U<br />في حالة الإصابة بارتفاع ضغط الدمَّ البسيط إلى معتدل، تناول قرصًا واحد ممتد الإفراز من كاريليو ٥۰ ، مرة واحدة يوميًا في<br />الصباح. قد يقوم الطبيب بزيادة الجرعة إلى قرص واحد ممتد الإفراز من كاريليو ۱۰۰ أو كاريليو ۲۰۰ . إذا لزم الأمر، فقد يصف<br />لك طبيبك دواءً إضافيًا خافضًا لضغط الدم.<br />الأطفال والمراهقون (بعمر ٦ إلى ۱٦ عامًا) U<br />بالنسبة للأطفال من عمر ٦ سنوات، تعتمد الجرعة على وزن الجسم. سيحدد طبيبك الجرعة الصحيحة لطفلك ويراقبها بانتظام.<br />لا يوصى باستخدام كاريليو من قبل الأطفال الذين تقل أعمارهم عن ٦ سنوات.<br />الذبحة الصدرية (ضيق في الصدر)<br />في حالة الإصابة بالذبحة الصدرية، تناول قرصًا واحدًا ممتد الإفراز من كاريليو ۱۰۰ أو كاريليو ۲۰۰ مرَّة واحدة يومياً. إذا كانت<br />هناك حاجة، فقد يقوم طبيبك بزيادة الجرعة.<br />فشل القلب المزمن (قصور مزمن بوظائف القلب)<br />في حالات فشل القلب المزمن، تكون الجرعة الأوَّلية من كاريليو ۲٥ مجم مرة واحدة يوميًا لمدة ۲ أسابيع.<br />في حالات فشل القلب الشديد، قد يصف لك الطبيب جرعة أوَّلية منخفضة بحجم ۱۲٫٥ مجم مرَّة واحدة يوميًا (نصف قرص ممتد<br />الإفراز من كاريليو ۲٥ مجم). من الممكن حينئذ مضاعفة الجرعة كل أسبوعين حتى تصل إلى ۲۰۰ مجم من كاريليو مرَّة واحدة<br />يومياً.<br />اضطرابات النظم القلبي<br />في حالة الإصابة باضرابات النظم القلبي، تناول قرصًا واحدًا ممتد الإفراز من كاريليو ۱۰۰ أو كاريليو ۲۰۰ مرَّة واحدة يومياً.<br />إذا كانت هناك حاجة، فقد يقوم طبيبك بزيادة الجرعة.<br />اضطرابات القلب والأوعية الدمَّوية المصحوبة بخفقان<br />في حالة الإصابة باضرابات القلب والأوعية الدموية، تناول قرصًا واحداً ممتد الإفراز من كاريليو ۱۰۰ مرَّة واحدة يومياً. إذا<br />كانت هناك حاجة، فقد يقوم طبيبك بزيادة الجرعة.<br />الوقاية من الصداع النصفي<br />للوقاية من الصداع النصفي، تناول قرصًا واحدًا ممتد الإفراز من كاريليو ۱۰۰ أو كاريليو ۲۰۰ مرَّة واحدة يومياً.<br />ا. 􀌒 يجب عدم إيقاف كاريليو فجأة. سيقرر طبيبك كيفية خفض الجرعة تدريجي<br />لا تغير الجرعة الموصوفة من تلقاء نفسك. إذا شعرت أن تأثير الدواء أقل من اللازم أو أقوى من اللازم، فاتصل بطبيبك أو<br />بالصيدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>قد تحدث الآثار الجانبية التاَّلية عند تناوُل كاريليو:<br />شائعة جدا: تعب. شائعة: دوخة، صداع، غثيان، ألم بالبطن، ضيق النفس، بطء النبض الغير طبيعي، برودة اليدين والقدمين،<br />الإسهال والإمساك.<br />غير شائعة: إنهاك، قيء، ألم حول القلب، وذمة (احتباس الماء في الأنسجة)، تقلصات عضلية، نعاس، عدم القدرة على النوم<br />(أرق)، كوابيس، ضعف التركيز، اكتئاب، زيادة التعرُّق، طفح جلدي، نوبات الربو، زيادة الوزن. نادرة: خَفَقان، عدم انتظام<br />ضربات القلب، فشل القلب، العصبية، القلق، اضطرابات بصرية، جفاف وتهيج العينين، التهاب بطانة الأنف، ضعف العضلات،<br />جفافُ الفَم، تساقط الشعر، اضطرابات الرغبة الجنسية واضطرابات بالانتصاب.<br />ا: تقلب الحالة المزاجية، ضعف الذاكرة، ارتباك/التباس، الهلاوس، طنين بالأذنين، اضطرابات التذوق، حساسية الجلد 􀌒 نادرة جد<br />تجاه الضوء، تفاقم الصدفية وألم بالمفاصل.<br />إذا لاحظت أية آثار جانبية غير مذكورة في هذه النشرة، فيجب عليك إخبار طبيبك أو الصيدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تحفظ الدَّواء في درجة حرارة تتجاوز ۲٥ درجة مئوية واحفظه بعيداً عن رؤية ومُتناوَل الأطفال.<br />على العبوة. إذا كانت لديك أدوية منتهية &laquo;EXP&raquo; من الممكن استخدام هذا الدوَّاء حتى تاريخ انتهاء الصلاحية المحدد بكلمة<br />الصلاحية، فقم بإعادتها إلى الصيدلية للتخلص منها.<br />قد يتم الحصول على معلومات إضافية من طبيبك أو الصيدلي الخاص بك. هؤلاء الأشخاص لديهم المعلومات الوصفية المفصلة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحتوي قرص واحد ممتد الإفراز من كاريليو ۲٥ ، و ٥۰ ، و ۱۰۰ و ۲۰۰ على ۲۳٫۷٥ مجم، و ٤۷٫٥ مجم، و ۹٥ مجم و ۱۹۰ مجم<br />على التوَّالي من سكسينات الميتوبرولول، ما يعادل ۲٥ مجم، و ٥۰ مجم، و ۱۰۰ مجم و ۲۰۰ مجم على التوَّالي من طرطرات<br />الميتوبرولول</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>تتوفر عبوات تحتوي على و ۳۰ ، و ٥۰ و ۱۰۰ قرصًا ممتد الإفراز (كاريليو ۲٥ ، كاريليو ٥۰ ، كاريليو ۱۰۰ ، كاريليو ۲۰۰</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>ج. مالك حق التسَّويق وجهة التصَّنيع<br />أسينو فارما إيه جي، ليزبيرج (سويسرا)</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            مارس 2015
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                CarelioTM 25/50/100/200 mg Retard Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Active substance: Metoprolol succinate.
Excipients: Excipients for coated tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One prolonged-release tablet contains 23.75 mg, 47.5 mg, 95 mg or 190 mg of metoprolol
succinate, equivalent to 25 mg, 50 mg, 100 mg or 200 mg of metoprolol tartrate respectively.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hypertension;<br />Angina pectoris (long-term prophylaxis);<br />Treatment of NYHA class II and III chronic heart failure, in addition to the standard<br />treatment;<br />Cardiac arrhythmias, especially supraventricular tachyarrhythmias;<br />Functional cardiovascular disorders with palpitations;<br />Prophylaxis of migraine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Carelio prolonged-release tablets are taken once daily with a glass of water. They can be<br />taken with or without meals. The Carelio prolonged-release tablets have a score line and can<br />be easily divided to allow dosage adjustment. They must not be chewed or crushed.<br />The following dosage guidelines apply:</p><p>Hypertension<br />Patients with mild or moderate hypertension: M 50 once daily in the morning.<br />For patients not responding to the Carelio 50 dose, Carelio 100 or Carelio 200 can be<br />administered once daily. If necessary, a further antihypertensive can additionally be<br />prescribed.<br />Hypertensive patients receiving long-term antihypertensive treatment with 100&ndash;200 mg of<br />Carelio once daily have shown a reduced mortality rate including sudden cardiac death as<br />well as a diminished rate of stroke and coronary events (see &ldquo;Properties/Effects&rdquo;).<br />Angina pectoris<br />Carelio 100 or Carelio 200 once daily.<br />In severe cases, the dose, given once daily, may be further increased.<br />Chronic heart failure<br />The dosage of Carelio should be adjusted individually for patients with chronic heart failure<br />who receive the standard therapy.<br />Starting dose: one 25 mg tablet once daily for 2 weeks.<br />The recommended starting dose for patients with NYHA class III heart failure is 12.5 mg<br />(half a 25 mg tablet) once daily during the first week of treatment. Thereafter, the dose can be<br />doubled every two weeks of treatment up to a maximum dose of 200 mg once daily. During<br />long-term therapy a maximum dose of 200 mg once daily (or the highest dose tolerated by the<br />individual patient) is recommended.<br />After each increase in the dose the tolerability of the treatment must be reviewed carefully. In<br />the event of hypotension a reduction in the dose(s) of the concomitant medication(s) will be<br />necessary. Incipient hypotension at the start of therapy does not necessarily mean that longterm<br />therapy will not be tolerated. In this case, however, the patient must take a lower dose<br />until his/her condition is stable.<br />Heart rhythm disorders<br />Carelio 100 or Carelio 200 once daily.<br />If necessary, the dose, given once daily, may be further increased.<br />Functional cardiovascular disorders with palpitations<br />Carelio 100 once daily.<br />If necessary, the dose, given once daily, may be further increased.<br />Prophylaxis of migraine<br />Carelio 100 or Carelio 200 once daily.<br />The treatment should not be stopped abruptly but tapered off, especially in patients with<br />coronary heart disease or after long-term use (See &ldquo;Warnings and precautions&rdquo;).<br />Special dosage instructions<br />Renal insufficiency<br />An adjustment of the dose is not necessary in patients with renal impairment.<br />Hepatic impairment<br />Because of low binding of metoprolol to plasma proteins (5-10%), a dose adjustment is<br />usually not necessary in patients with mild hepatic impairment. However, in patients with<br />severe hepatic impairment (e.g. patients who have undergone shunt surgery) the dose should<br />be adjusted accordingly.<br />Elderly patients<br />An adjustment of the dose is not necessary in elderly patients.<br />Paediatric population<br />The recommended starting dose for hypertensive patients &gt; 6 years old is 1.0 mg/kg<br />metoprolol, with a maximum of 50 mg/day. This dose is administered once daily and must be<br />approximated to the Carelio tablets dose strengths. In patients who are not responsive to<br />1.0 mg/kg, the dose can be increased to a maximum of 2.0 mg/kg. Doses higher than 200 mg<br />once daily have not been studied in children and adolescents.<br />Efficacy and safety of use in children &lt; 6 years old have not been studied.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Known hypersensitivity to the active substance metoprolol, other beta-receptor blockers and
related derivatives or to any of the excipients.
Second- or third-degree atrioventricular block, congestive heart failure (pulmonary oedema,
impaired blood flow or hypotension), concomitant continuous or intermittent inotropic
treatment with beta-agonists, clinically manifest sinus bradycardia, sick sinus syndrome
(except in patients with a permanent pacemaker), severe peripheral arterial circulatory
disturbances, cardiogenic shock, hypotension, bradycardia (pulse rate < 50 beats/min),
untreated phaeochromocytoma (see “Warnings and precautions”).
In cases of suspected acute myocardial infarction, patients should not take Carelio when the
heart rate is < 45 beats/min, the PQ interval is > 0.24 sec or systolic blood pressure is
< 100 mmHg. Carelio must also not be taken in the presence of severe heart failure (NYHA
class IV).
A history of severe bronchial asthma or severe bronchospasm
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients being treated with beta-receptor blockers should not receive intravenous<br />administrations of verapamil-type calcium antagonists.<br />In general, patients being treated for hypertension with concomitant obstructive pulmonary<br />disease should not receive beta-receptor blockers. Because of its cardioselectivity, Carelio can<br />still be administered in cases where relevant other medicines such as diuretics are not<br />tolerated or are ineffective. In such circumstances, the lowest effective dose must be chosen<br />and the dosage of the beta-2 stimulant must be re-adjusted.<br />Carelio may lead to an increased plasma concentration in the presence of genetically induced<br />debrisoquine polymorphism in poor metabolisers.<br />Metoprolol influences insulin release and carbohydrate metabolism to a lesser extent than<br />non-selective beta-receptor blockers. Unlike non-selective beta-receptor blockers, metoprolol<br />only partially masks hypoglycaemic symptoms in diabetic patients. Caution is nevertheless<br />advised. Diabetic patients should be warned that beta-receptor blockers can attenuate<br />tachycardia associated with hypoglycaemia; other signs of hypoglycaemia such as lightheadedness<br />or sweating may not be significantly suppressed. Sweating may even be<br />increased.</p><p>atients with pre-existing cardiac decompensation should be treated for this before and during<br />metoprolol therapy.<br />A moderate AV conduction abnormality may worsen (to the point of AV block).<br />Metoprolol may exacerbate peripheral arterial circulatory disorders, mainly due to its<br />antihypertensive effect.<br />If metoprolol is given to patients with known phaeochromocytoma, an alpha-receptor blocker<br />should be administered concomitantly (see &ldquo;Contraindications&rdquo;).<br />In the case of liver cirrhosis, the bioavailability of beta-receptor blockers may be enhanced,<br />leading to an increase in plasma concentrations.<br />Abrupt discontinuation of therapy is dangerous, particularly in high-risk patients, and must<br />therefore be avoided.<br />Beta-receptor blocker medication should not be discontinued during surgery. Before surgery<br />the anaesthetist should be informed that the patient is being treated with metoprolol.<br />Patients undergoing surgery that does not involve the heart should not receive initial acute<br />treatment with high doses of metoprolol as this has been shown to be associated with<br />bradycardia, hypotension and stroke (including with a fatal outcome) in patients with<br />cardiovascular risk factors.<br />Following abrupt cessation of therapy with certain beta-blocking agents, exacerbations of<br />angina pectoris and, in some cases, myocardial infarction have occurred. When discontinuing<br />chronically administered metoprolol succinate extended-release tablets, particularly in<br />patients with ischemic heart disease, the dosage should be gradually reduced over a period of<br />1 - 2 weeks and the patient should be carefully monitored. If angina markedly worsens or<br />acute coronary insufficiency develops, metoprolol succinate extended-release tablet<br />administration should be reinstated promptly, at least temporarily, and other measures<br />appropriate for the management of unstable angina should be taken. Warn patients against<br />interruption or discontinuation of therapy without the physician&#39;s advice. Because coronary<br />artery disease is common and may be unrecognized, it may be prudent not to discontinue<br />metoprolol succinate extended-release tablet therapy abruptly even in patients treated only for<br />hypertension.<br />If treatment with Carelio is to be stopped, the metoprolol dose must be reduced gradually, if<br />possible, over a minimum of 2 weeks. It is recommended that half the dose (a tablet with a<br />lower active substance content) be taken each time until the final step, when half a 25 mg<br />tablet should be taken. The final dose level of 12.5 mg should be taken for at least 4 days<br />before treatment is stopped. If any symptoms appear during this cessation phase, dose<br />reduction must be slower. Abrupt cessation of the treatment may exacerbate chronic heart<br />failure and increase the risk of myocardial infarction and sudden cardiac death.<br />Patients with ischaemic heart disease in particular should be closely monitored during this<br />phase. The risk of coronary events including sudden cardiac death may be increased in the<br />beta-receptor blocker cessation phase.<br />Patients taking beta-receptor blockers who experience anaphylactic shock tend to show a<br />more severe form.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Metoprolol enhances the effect of other antihypertensive medicinal products. Special caution<br />is advised when a beta-receptor blocker is used concomitantly with prazosin for the first time.<br />Patients concomitantly receiving sympatholytic medicinal products, other beta-receptor<br />blockers (including in the form of eye drops) or MAO inhibitors should be monitored.<br />Nitroglycerine may enhance the antihypertensive effect of beta-receptor blockers.<br />If concomitant therapy with clonidine is to be terminated, therapy with the beta-receptor<br />blocker must be ended several days prior to clonidine.<br />When administered concomitantly with calcium channel blockers (of the verapamil/diltiazem<br />type) and/or anti-arrhythmic agents, attention should be paid to the possible occurrence of a<br />negative inotropic and chronotropic effect. Patients being treated with beta-receptor blockers<br />should not receive calcium channel blockers of the verapamil type intravenously.<br />Beta-receptor blockers may enhance the negative inotropic and negative dromotropic effects<br />of anti-arrhythmic agents (of the quinidine type and amiodarone).<br />Inhalation anaesthetics enhance the cardiodepressant effect in the presence of beta-receptor<br />blockade. Digitalis glycosides in association with beta-receptor blockers may increase<br />atrioventricular conduction time and induce bradycardia.<br />Metoprolol is a substrate of the cytochrome P450 isoenzyme CYP2D6. Substances that act as<br />enzyme inducers and enzyme inhibitors may therefore alter plasma concentrations of<br />metoprolol.<br />Co-administration with substances that are metabolised by CYP2D6, such as anti-arrhythmic<br />agents (e.g. amiodarone, quinidine), anti-histamine agents (e.g. diphenhydramine),<br />H2 receptor antagonists (e.g. cimetidine), antidepressants (e.g. clomipramine, selective<br />serotonin reuptake inhibitors [SSRIs]), antipsychotics (e.g. haloperidol) and COX-2 inhibitors<br />(e.g. celecoxib) as well as ritonavir, may increase plasma metoprolol concentrations. This<br />may potentiate the hypotensive effect of Carelio.<br />This must be taken into consideration when titrating the Carelio dose and attention must be<br />paid to the possibility of adverse effects, e.g. bradycardia.<br />Rifampicin may reduce the plasma metoprolol level. This may attenuate the hypotensive<br />effect of Carelio.<br />Alcohol may increase the plasma metoprolol concentration.<br />Concomitant treatment with indomethacin and some other inhibitors of prostaglandin<br />synthesis may reduce the antihypertensive effect of metoprolol.<br />When co-administered with adrenaline or other sympathomimetic substances (e.g. as<br />contained in cough remedies, nasal drops and eye drops), cardioselective beta-receptor<br />blockers in therapeutic doses lead to less pronounced hypertensive reactions than nonselective<br />beta-receptor blockers.<br />Caution is advised when treating diabetic patients with beta-receptor blockers. The diabetic<br />treatment should be adjusted.<br />Metoprolol may reduce the clearance of other medicinal products (e.g. lidocaine).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />Metoprolol should not be taken during pregnancy unless absolutely necessary.<br />There are no controlled studies in pregnant women.<br />In general, beta-receptor blockers reduce placental perfusion. Human studies have shown<br />indications of impaired placental perfusion due to metoprolol. This was associated with<br />growth retardation, intrauterine foetal death, abortion and premature labour. It is therefore<br />recommended that appropriate foetomaternal monitoring be performed in pregnant women<br />treated with metoprolol. Beta-receptor blockers may induce bradycardia in the foetus,<br />neonates or infants when breast feeding.<br />Animal studies have shown no direct or indirect toxicity affecting pregnancy, embryonic<br />development, foetal health and/or post-natal development.<br />Due to the possible development of adverse reactions, e.g. bradycardia, hypotension and<br />hypoglycaemia, in the neonate, therapy with metoprolol should be discontinued 48&ndash;72 hours<br />before the estimated time of delivery. If this is not possible, newborns must be carefully<br />monitored by a physician for 48&ndash;72 hours after delivery.<br />Lactation<br />Metoprolol should not be taken while breastfeeding unless absolutely necessary. Metoprolol<br />is excreted in human milk. At the time of delivery, serum concentrations in mother and child<br />are comparable. In breast milk, metoprolol reaches approximately three-fold the serum<br />concentration measured in the mother. With daily oral dosing of 200 mg metoprolol,<br />approximately 225 micrograms are excreted per litre of milk. Although the amount of active<br />substance ingested with breast milk is unlikely to pose any risk to the child, infants should be<br />monitored for signs of beta-blockade.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Carelio may impair patients&rsquo; reaction time when driving vehicles or using machines, as<br />dizziness is common and fatigue very common.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following adverse effects have been mainly observed in clinical trials and during daily<br />use of conventional metoprolol tablets (metoprolol tartrate).<br />Blood and lymphatic system disorders<br />Very rare: Thrombocytopenia.<br />Psychiatric disorders<br />Uncommon: Depression, reduced concentration, somnolence or insomnia, nightmares.<br />Rare: Nervousness, anxiety.<br />Very rare: Personality changes (e.g. mood swings), amnesia/impaired memory, confusion,<br />hallucinations.<br />Nervous system disorders<br />Very common: Fatigue.<br />Common: Dizziness, headache.<br />Uncommon: Paraesthesia, asthenia.<br />Rare: Muscle weakness.<br />Eye disorders<br />Rare: Visual disturbances, dry and irritated eyes, conjunctivitis, reduced lachrymal secretion.<br />Ear and labyrinth disorders<br />Very rare: Tinnitus<br />Cardiac disorders<br />In common with all anti-arrhythmic agents, the treatment of rhythm disorders with betareceptor<br />blockers may cause arrhythmogenic effects.<br />Common: Bradycardia, palpitations.<br />Uncommon: Transient deterioration of the symptoms of heart failure, cardiogenic shock in<br />patients with acute myocardial infarction, 1st degree AV block, oedema, precordial pain.<br />Rare: Cardiac conduction disorders, heart failure, cardiac arrhythmias, Raynaud&rsquo;s syndrome.<br />Vascular disorders<br />Common: Orthostatic disorders (very rarely associated with syncope), cold hands and feet.<br />Very rare: Gangrene in patients with existing severe circulatory disturbances.<br />Respiratory, thoracic and mediastinal disorders<br />Common: Exertional dyspnoea.<br />Uncommon: Bronchospasm, even in patients with no known history of obstructive pulmonary<br />disease.<br />Rare: Rhinitis.<br />Gastrointestinal disorders<br />Common: Nausea, abdominal pain, diarrhoea or constipation.<br />Uncommon: Vomiting.<br />Rare: Dry mouth.<br />Very rare: Taste alterations.<br />Hepatobiliary disorders<br />Rare: Liver function test abnormalities.<br />Very rare: Hepatitis.<br />Skin and subcutaneous tissue disorders<br />Uncommon: Erythema, rash (in the form of urticaria and psoriasiform and dystrophic skin<br />changes), increased sweating.<br />Rare: Alopecia.<br />Very rare: Photosensitivity, exacerbation of psoriasis.<br />Musculoskeletal and connective tissue disorders<br />Very rare: Arthralgia.<br />Uncommon: Muscle cramps.<br />Reproductive system<br />Rare: Libido disorders and impotence.<br />General disorders<br />Uncommon: Weight gain.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms<br />Symptoms of overdose can include hypotension, heart failure, bradycardia/bradyarrhythmia,<br />cardiac conduction abnormalities, atrioventricular block, cardiogenic shock, cardiac arrest,<br />bronchospasm, disorders of consciousness (up to coma), nausea, vomiting and cyanosis.<br />Concomitant ingestion of alcohol, antihypertensives, quinidine or barbiturates potentiates the<br />signs and symptoms.<br />Measures<br />In the event of an overdose, the clinically necessary measures should be taken to stabilise and<br />monitor the patient&rsquo;s vital signs.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ATC code: C07AB02<br />Carelio is a controlled-release formulation for once-daily oral administration.<br />The prolonged-release tablet contains the active substance metoprolol succinate in a large<br />number of pellets. Each pellet is coated with a polymeric membrane. After ingestion, the<br />tablet dissolves very rapidly and the pellets disperse in the gastrointestinal tract and release<br />metoprolol there continuously for 20 hours. The release rate is independent of physiological<br />factors such as pH or peristalsis.<br />Metoprolol, the active substance in Carelio, is a cardioselective beta-1-receptor blocker. It<br />acts on beta-1 receptors, which are mainly located in the heart, at lower doses than required to<br />influence beta-2 receptors, which are mainly located in the bronchi and peripheral vessels.<br />Metoprolol does not have a membrane-stabilising effect or a partial agonist effect (intrinsic<br />sympathomimetic activity = ISA).<br />Metoprolol decreases or inhibits the agonist effects of catecholamines which cause an<br />increase in heart rate, cardiac output, cardiac contractility and blood pressure.</p><p>At high endogenous adrenaline levels, metoprolol has less effect on the control of blood<br />pressure than non-selective beta-receptor blockers.<br />The Carelio formulation leads to a balanced plasma concentration profile and an even effect<br />(&beta;1 blockade) over 24 hours, unlike conventional tablet formulations of beta-1 blockers,<br />including metoprolol tartrate. Marked plasma concentration peaks do not occur on Carelio,<br />which improves clinical beta-1 selectivity. Therefore, adverse effects due to high plasma<br />concentration peaks, such as bradycardia and tired legs, are reduced.<br />In general, patients being treated for hypertension with concomitant obstructive pulmonary<br />disease should not receive beta-receptor blockers. Metoprolol can be administered in<br />combination with a beta-2 agonist to patients with obstructive pulmonary disease in cases<br />where relevant other medicines such as diuretics are not tolerated or are ineffective. Within<br />the therapeutic dose range, metoprolol counteracts the bronchodilation caused by beta-2<br />agonists less strongly than a non-selective beta-receptor blocker (see &ldquo;Warnings and<br />precautions&rdquo;).<br />Metoprolol influences insulin release and carbohydrate metabolism to a lesser extent than<br />non-selective beta-receptor blockers. Metoprolol affects cardiovascular response to<br />hypoglycaemia less than non-specific beta-receptor blockers. Caution is nevertheless advised.<br />Sensitivity to insulin may decrease on long-term treatment with metoprolol.<br />Short-term studies show that metoprolol may cause a slight increase in triglyceride levels and<br />a decrease in free fatty acids in the blood. In some cases, a slight decrease in the HDL fraction<br />has been noted, albeit to a lesser extent than with non-selective beta-receptor blockers. A<br />long-term study over several years showed a significant decrease in the cholesterol level.<br />Metoprolol treatment may enhance quality of life. Improved quality of life has been observed<br />in patients following myocardial infarction. The treatment has also enhanced the quality of<br />life of patients with chronic heart failure.<br />Effect on hypertension<br />Metoprolol has an antihypertensive effect in standing as well as lying patients.<br />At the beginning of treatment, metoprolol initially causes an increase in peripheral vascular<br />resistance.<br />During long-term treatment, a decrease in total peripheral resistance can be obtained due to<br />the regression of hypertrophy in the peripheral arterial vessels.<br />Long-term antihypertensive treatment with metoprolol has also achieved a reduction in leftventricular<br />hypertrophy and at the same time improved ventricular function/filling.<br />A 4-week study performed in 144 children and adolescents (from 6 to 16 years old) with<br />essential hypertension showed that 1.0 and 2.0 mg/kg metoprolol can reduce placebocorrected<br />systolic blood pressure (4 to 6 mmHg). A greater decrease in diastolic blood<br />pressure (5 mmHg) was observed with the dose of 2.0 mg/kg versus placebo. No evident<br />differences were found as a function of age, Tanner stage or race.<br />It has been noted that metoprolol treatment reduces the risk of death from cardiovascular<br />disease in cases of mild to moderate hypertension, especially due to a lowering of the risk</p><p>factor of &ldquo;sudden cardiovascular death&rdquo;. At the same time, these patients have a lower risk of<br />non-fatal or fatal myocardial infarction or of stroke.</p><p>Effect on angina pectoris<br />In angina pectoris patients, metoprolol decreases the frequency, the length and the intensity of<br />angina attacks. Moreover, metoprolol increases physical exercise tolerance.<br />Effect on chronic heart failure<br />In NYHA class II and III heart failure patients with an ejection fraction of &le;40%, the use of<br />Carelio in addition to the standard treatment leads to an improvement in the survival rate and<br />a reduction in the number of hospitalisations normally required due to a worsening of heart<br />failure.<br />Carelio treatment has also allowed the following objectives to be achieved:<br />‒ improvement in functional NYHA class;<br />‒ improvement in quality of life.<br />Effect on cardiac rhythm<br />Metoprolol is used to regulate the heart rate in cases of supraventricular tachycardia, atrial<br />fibrillation and ventricular extrasystole.<br />Effect on functional cardiac disorders with palpitations<br />Carelio is suitable for the treatment of functional cardiac disorders with palpitations.<br />Its effect on myocardial infarction has also been studied. In cases of suspected or confirmed<br />myocardial infarction, metoprolol reduces mortality by reducing the risk of sudden cardiac<br />death. This effect may be based on a preventive action against ventricular fibrillation. This<br />inhibitory effect on ventricular fibrillation is probably based on a dual mechanism: on the one<br />hand, a vagal effect, which has a positive influence on the electrophysiological stability of the<br />heart, and, on the other hand, a sympathetically mediated anti-ischaemic effect, which<br />improves contractility and heart rate and stabilises blood pressure.<br />After early or late intervention, a reduction in mortality has been demonstrated in high-risk<br />patients with a history of cardiovascular disorders as well as in patients with diabetes mellitus<br />and/or congestive heart failure. Metoprolol administration has also been shown to decrease<br />the frequency of non-fatal reinfarctions.<br />Carelio can also be used as an additional treatment in cases of hyperthyroidism.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption/Distribution<br />Metoprolol is almost completely absorbed after oral administration. Due to an extensive firstpass<br />effect, systemic bioavailability following a single oral dose is approximately 50%. The<br />bioavailability of the prolonged-release tablets (delayed active-substance release) is<br />approximately 20-30% lower than that of conventional tablets. This reduction has, however,<br />been shown not to be clinically significant because the &ldquo;area under the effect curve&rdquo; (AUEC)<br />in terms of heart rate is identical for both formulations.<br />Only a small fraction of metoprolol, approximately 5-10%, is bound to plasma proteins.<br />Each prolonged-release tablet consists of several hundred pellets containing metoprolol<br />succinate. Each pellet is surrounded by a polymeric membrane, which controls metoprolol<br />succinate release.<br />After ingestion, the prolonged-release tablet disintegrates rapidly and the pellets are released<br />in the gastrointestinal tract. Metoprolol is released continuously for 20 hours. The elimination</p><p>half-life of metoprolol is 3.5 hours (see &ldquo;Metabolism / Elimination&rdquo;). This is the reason why a<br />balanced plasma level is achieved over a dosing interval of 24 hours. Metoprolol succinate<br />release is independent of pH and peristalsis.<br />Metabolism<br />Metoprolol is metabolised by oxidation in the liver, mainly by CYP2D6. Three major<br />metabolites without a pharmacological effect can be identified.<br />Carelio may lead to an increased plasma concentration in the presence of genetically induced<br />debrisoquine polymorphism in poor metabolisers.<br />Elimination<br />As a rule, approximately 95% of an oral dose of metoprolol can be recovered in the urine.<br />Approximately 5% of the dose is excreted unchanged in the urine. In isolated cases, this<br />figure can rise to 30%. The plasma half-life of metoprolol amounts to an average of 3.5 hours<br />(extremes: 1 and 9 hours). Total clearance is about 1 L/min.<br />Kinetics in special patient groups<br />Elderly patients<br />The pharmacokinetics of metoprolol is unchanged in elderly patients compared with younger<br />patients.<br />Paediatric population<br />The pharmacokinetic profile of metoprolol in children and adolescents (6 to 16 years old) is<br />similar to that in adults. Oral clearance (CL/F) seems to increase linearly with body weight.<br />Renal insufficiency<br />The systemic bioavailability and the elimination of metoprolol are unchanged in patients with<br />impaired renal function. Elimination of the metabolites, however, is reduced. Significant<br />metabolite accumulation has been observed in patients with a glomerular filtration rate (GFR)<br />of about 5 mL/min. However, this does not lead to an increased beta-receptor blocking effect<br />of metoprolol.<br />Hepatic impairment<br />Increased plasma levels of unchanged metoprolol must be expected in liver cirrhosis due to<br />the reduced biotransformation rate.<br />In patients with severe liver cirrhosis and a portacaval shunt, the bioavailability of metoprolol<br />may be increased and total clearance decreased. Patients with a portacaval shunt have a total<br />elimination rate of approximately 0.3 L/min and the area under the plasma concentration/time<br />curve (AUC) values are approximately six times higher than in healthy subjects.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mutagenic and tumorigenic potential<br />Metoprolol has not been subject to extensive mutagenicity testing; previous studies have<br />shown no indications of a mutagenic potential.<br />Results from carcinogenicity studies in rats and mice are available, from which no<br />tumorigenic potential can be inferred.<br />Reproductive toxicity</p><p>Studies on two animal species (rat, rabbit) have shown no indications of any teratogenic<br />properties for metoprolol.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Excipients:<br />Tablet core:<br />Sugar spheres, Macrogol 6000, Polyacrylate dispersion 30%, Talc, Povidone, Cellulose<br />microcrystalline, Magnesium stearate, Colloidal Silica anhydrous.<br />Tablet coating:<br />Hypromellose, Talc, macrogol 6000, Titanium dioxide (E171).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None known to date.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 25&deg;C.<br />Store out of the sight and reach of children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aluminium/Aluminium blister and/or HDPE bottles with PP twist-off caps.<br />Packs:<br />Carelio 25: 30, 50, 100.<br />Carelio 50: 30, 50, 100.<br />Carelio 100: 30, 50, 100.<br />Carelio 200: 30, 50, 100.<br />Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Acino Pharma AG, Liesberg (Switzerland)
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                October 2018
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>